Cargando…
Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
SIMPLE SUMMARY: Currently, a combination therapy of standard androgen deprivation therapy (ADT) plus docetaxel or androgen receptor-axis-targeted therapy is the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Compared to ADT monotherapy, combination treatment prolon...
Autores principales: | Thomas, Christian, Baunacke, Martin, Erb, Holger H. H., Füssel, Susanne, Erdmann, Kati, Putz, Juliane, Borkowetz, Angelika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750314/ https://www.ncbi.nlm.nih.gov/pubmed/35008172 http://dx.doi.org/10.3390/cancers14010008 |
Ejemplares similares
-
Retrospective Real-world Evaluation of Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) during the COVID-19 Pandemic Compared to Docetaxel in mHSPC Pre-COVID-19
por: Gould, A., et al.
Publicado: (2023) -
Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis
por: Ko, Gilbert Chao, et al.
Publicado: (2022) -
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
por: Ng, Kenrick, et al.
Publicado: (2020) -
Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure: detailed real-life data of complications and additional surgical procedures in 295 cases
por: Latarius, Stefanie, et al.
Publicado: (2023) -
Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events
por: Hall, F., et al.
Publicado: (2019)